TaiGen Biopharmaceuticals Holdings Limited
Taipei Exchange 4157.TWO
TaiGen Biopharmaceuticals Holdings Limited EBITDA for the year ending December 31, 2023: USD 5.61 M
-
TaiGen Biopharmaceuticals Holdings Limited EBITDA for the year ending December 31, 2022 was USD -6.54 M, a -119.52% change year over year.
-
TaiGen Biopharmaceuticals Holdings Limited EBITDA for the year ending December 31, 2021 was USD 33.49 M, a 459.81% change year over year.
-
TaiGen Biopharmaceuticals Holdings Limited EBITDA for the year ending December 31, 2020 was USD -9.31 M, a -5.09% change year over year.
-
TaiGen Biopharmaceuticals Holdings Limited EBITDA for the year ending December 31, 2019 was USD -8.86 M, a 18.48% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Mr. Kuo-Lung Huang |
| IPO Date | Aug. 30, 2013 |
| Location | Taiwan |
| Headquarters | No. 138, Xinming Road |
| Employees | 52 |
| Sector | Health Care |
| Industries | |
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
Past 5 years
USD 0.93
USD 0.49
USD 0.93
USD 0.93
StockViz Staff
January 15, 2025
Any question? Send us an email